CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishWe have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin ctl (Toll) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations. 5-FU was delivered loco-regionally as a continuous infusion via an intraperitoneal (i.p.) catheter from a subcutaneously implanted mini-pump, a method we developed for this study. We show here that two cycles of a triple chemo-immunotherapy regimen significantly increased the average survival time compared to one cycle, and compared to untreated controls or those treated with two cycles of 5-FU alone. At 150 days, two rats treated with two cycles of triple therapy were cured, showing no signs of cancer at autopsy; all the other rats died before this time. Triple chemo-immunotherapy resulted in significantly fewer extra-hepatic metastases than in the controls and in those treated with 5-FU only. Further, we found that two cycles of triple treatment significantly increased the absolute number of peripheral T cells expressing IL-2 receptor, CD4 and CD8 compared to controls. We conclude that two cycles of chemo-immunotherapy with 5-FU, Toll and IL-2 were superior to one cycle of treatment and to other treatments tested. Our results suggest that the triple therapy acts by increasing numbers of effector T cells. This method shows promise for the use of multi-cycle chemo-immunotherapy in the treatment of unresectable metastases of colorectal cancer in humans.
Silecchia G., G.E. (1999). Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 48(4), 172-178.
| Tipologia: | Articolo su rivista | |
| Citazione: | Silecchia G., G.E. (1999). Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 48(4), 172-178. | |
| IF: | Con Impact Factor ISI | |
| Lingua: | English | |
| Settore Scientifico Disciplinare: | Settore MED/07 - Microbiologia e Microbiologia Clinica | |
| Revisione (peer review): | Sì, ma tipo non specificato | |
| Tipo: | Articolo | |
| Rilevanza: | Rilevanza internazionale | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s002620050562 | |
| Stato di pubblicazione: | Pubblicato | |
| Data di pubblicazione: | 1999 | |
| Titolo: | Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery | |
| Autori: | ||
| Autori: | Silecchia G., Guarino E., Sinibaldi-Vallebona P., Pierimarchi P., Restuccia A., Spaziani E., Bernard P., Tuthill C., Garaci E., Rasi G. | |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
Copyright © 2021